IMWG International uniform response for multiple myeloma
This paper, written by an expert panel on behalf of the International Myeloma Working Group, addresses the need for new uniform response criteria for myeloma patients.
IMWG Consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation
This article, produced by the International Myeloma Working Group, reviews the current literature and provides important perspectives and guidance on the major issues surrounding the optimal current management of transplantation-eligible myeloma patients.
IMWG Guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation
This paper provides an update to the first guideline published in 2005 by the International Myeloma Working Group on the management of myeloma patients who are ineligible for high-dose therapy and autologous stem cell transplantation. It includes recommendations on the diagnosis and treatment of these patients together with the management of side-effects of treatment.
IMWG Recommendations for the treatment of multiple myeloma-related bone disease
This paper, written by an interdisciplinary panel of experts in myeloma and myeloma bone disease, reviews the available evidence and provides recommendations for the management of myeloma-related bone disease. It also includes expert consensus to propose additional recommendations where there were insufficient published data.
UKMF Guidelines on the diagnosis and management of solitary plasmacytomas: 2009 update
This paper provides updated guidelines on the diagnosis and management of solitary plasmacytoma of bone, extramedullary plasmacytoma and multiple solitary plasmacytomas and incorporates further available information on diagnosis, prognosis and management and a new section on the management of multiple solitary plasmacytomas.
Guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance
These guidelines, written by the UK Myeloma Forum in conjunction with the Nordic Myeloma Study Group provide guidance for the effective clinical investigation of patients with newly detected paraprotein and the practical management of patients with monoclonal gammopathy of undetermined significance (MGUS).